Market Research Logo

Global Diabetes Drugs Market Forecast 2019-2027

Global Diabetes Drugs Market Forecast 2019-2027
KEY FINDINGS

The growth in the global diabetes drugs market is mainly driven by increased diabetic population and obesity rates in recent years. The North American market holds the largest share of the global market. The global diabetes drugs market is expected to grow at a CAGR of 6.50% during the forecast period of 2019-2027.

MARKET INSIGHTS

The important driver for the growth in this market is the increase in the prevalence of diabetes which is because of the increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The diabetes drugs market segments include diabetes type and product class. Diabetes drugs manufacturers offer products for use by both the types (type 1 and type 2) of diabetic patients. Growing elderly population is also influencing the market growth in a big way as the life expectancy rate is rising and the birth rate is declining at the same time.

REGIONAL INSIGHTS

The major countries considered in every region are North America (The United States and Canada), Europe (Germany, United Kingdom, France, Italy, and Rest of Europe) and Asia-Pacific (China, India, Japan, South Korea and Rest of Asia Pacific). Rising prevalence of diabetes and obesity rate is anticipated to be the key factors for the growth of the diabetes market. Global vendors are expanding their business by establishing their manufacturing facilities in developing countries. Vendors are focusing on strategic collaborations with domestic distribution partners and suppliers to improve their distribution channels.

COMPETITIVE INSIGHTS

Leading brands in the global market of diabetes drugs are Eli Lilly And Company, AstraZeneca Plc., B.Braun Melsungen Ag, Novo Nordisk A/S, Sanofi, Diavacs Inc., Xoma Corp., Albireo Pharma Inc., Macrogenics Inc., Astellas Pharma, Glaxosmithkline, Merck, Pfizer and Xeris Pharmaceuticals.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Rising Prevalence Of Type 2 Diabetes
3.2.2. Insulin Market Is Anticipated To Generate The Highest Revenue
4. Market Determinants
4.1. Market Drivers
4.1.1. Increase In Prevalence Of Diabetes
4.1.2. Advances In Insulin Technology
4.1.3. Growing Elderly Population
4.2. Market Restraints
4.2.1. Lack Of Awareness Among People
4.2.2. Cost Sensitivity Issues
4.3. Market Opportunities
4.3.1. Development Of New Formulations
4.3.2. Increasing Research And Development
4.4. Market Challenges
4.4.1. Fierce Market Competition
4.4.2. Rising Concerns In Scientific Community
4.4.3. Gaps In National-level Diabetes Management Plans
4.4.4. Poor Storage Conditions And Distribution Policies For Insulin
5. Market Segmentation
5.1. Market By Diabetes Type 2019-2027
5.1.1. Type 1
5.1.2. Type 2
5.2. Market By Product Class 2019-2027
5.2.1. Insulin
5.2.1.1. Fast Acting Insulin
5.2.1.2. Intermediate Acting Insulin
5.2.1.3. Long-acting Insulin
5.2.2. Non-insulin
5.2.2.1. Dpp-4 Inhibitor
5.2.2.2. Glp-1 Receptors Agonists
5.2.2.3. Sglt-2 Inhibitors
5.2.2.4. Other Non-insulin Drugs
6. Key Analytics
6.1. Porters Five Forces Analysis
6.1.1. Threat Of New Entrants
6.1.2. Threat Of Substitute
6.1.3. Bargaining Power Of Suppliers
6.1.4. Bargaining Power Of Buyers
6.1.5. Threat Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Etymology Of Diabetes Drugs Market
6.4. Legal, Policy And Regulatory Issues
7. Geographical Analysis
7.1. Asia-pacific (Apac)
7.1.1. China
7.1.2. India
7.1.3. Australia
7.1.4. Japan
7.1.5. South Korea
7.1.6. Indonesia
7.1.7. Malaysia
7.1.8. Philippines
7.1.9. Thailand
7.1.10. Viet Nam
7.1.11. Rest Of Asia-pacific (Roapac)
8. Company Profiles
8.1. Eli Lilly And Company
8.1.1. Overview
8.1.2. Products Portfolio
8.1.3. Swot Analysis
8.1.4. Strategic Initiatives
8.2. Astrazeneca Plc.
8.2.1. Overview
8.2.2. Product Portfolio
8.2.3. Swot Analysis
8.2.4. Strategic Initiatives
8.3. B.Braun Melsungen Ag
8.3.1. Overview
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Analysis
8.4. Novo Nordisk A/S
8.4.1. Overview
8.4.2. Products Portfolio
8.4.3. Swot Analysis
8.4.4. Strategic Initiatives
8.5. Sanofi
8.5.1. Overview
8.5.2. Products Portfolio
8.5.3. Swot Analysis
8.5.4. Strategic Initiatives
8.6. Diavacs Inc.
8.6.1. Overview
8.6.2. Product Portfolio
8.6.3. Swot Analysis
8.7. Xoma Corp.
8.7.1. Overview
8.7.2. Product Portfolio
8.7.3. Swot Analysis
8.7.4. Strategic Initiatives
8.8. Albireo Pharma Inc.
8.8.1. Overview
8.8.2. Product Portfolio
8.8.3. Swot Analysis
8.9. Macrogenics, Inc.
8.9.1. Overview
8.9.2. Product Portfolio
8.9.3. Swot Analysis
8.10. Astellas Pharma
8.10.1. Overview
8.10.2. Product Portfolio
8.10.3. Swot Analysis
8.10.4. Strategic Initiatives
8.11. Glaxosmithkline
8.11.1. Overview
8.11.2. Product Portfolio
8.11.3. Swot Analysis
8.12. Merck
8.12.1. Overview
8.12.2. Product Portfolio
8.12.3. Swot Analysis
8.12.4. Strategic Initiatives
8.13. Pfizer
8.13.1. Overview
8.13.2. Product Portfolio
8.13.3. Swot Analysis
8.13.4. Strategic Initiatives
8.14. Xeris Pharmaceuticals
8.14.1. Overview
8.14.2. Product Portfolio
8.14.3. Swot Analysis
8.14.4. Strategic Initiatives
Table List
Table 1 Asia Pacific Diabetes Drugs Market 2019-2027 ($ Million)
Table 2 Asia Pacific Diabetes Drugs Market By Diabetes Types 2019-2027, ($ Million)
Table 3 Asia Pacific Diabetes Drugs Market In Type 1 Diabetes 2019-2027 ($ Million)
Table 4 Asia Pacific Diabetes Drugs Market In Type 2 Diabetes 2019-2027 ($ Millions)
Table 5 Asia Pacific Diabetes Drugs Market By Product Class 2019-2027 ($ Millions)
Table 6 Asia Pacific Diabetes Drugs Market In Insulin Type 2019-2027 ($ Million)
Table 7 Asia Pacific Diabetes Drugs Market In Insulin By Types 2019-2027 ($ Million)
Table 8 Asia Pacific Insulin Market In Fast Acting Insulin 2019-2027 ($ Million)
Table 9 Asia Pacific Insulin Market In Intermediate Acting Insulin 2019-2027 ($ Million)
Table 10 Asia Pacific Insulin Market In Long Acting Insulin 2019-2027 ($ Million)
Table 11 Asia Pacific Diabetes Drugs Market In Non-insulin Drugs 2019-2027 ($ Million)
Table 12 Asia Pacific Diabetes Drugs Market In Non-insulin Drugs By Types 2019-2027 ($ Million)
Table 13 Asia Pacific Non-insulin Drugs Market In Dpp-4 Inhibitor 2019-2027 ($ Million)
Table 14 Asia Pacific Non-insulin Drugs Market In Glp-1 Receptors Agonists 2019-2027 ($ Million)
Table 15 Asia Pacific Non-insulin Drugs Market In Sglt-2 Inhibitors 2019-2027 ($ Million)
Table 16 Asia Pacific Non-insulin Drugs Market In Other Non-insulin Drugs 2019-2027 ($ Million)
Table 17 Asia-pacific Diabetes Drugs Market By Country 2019-2027 ($ Million)
Figures List
Figure 1 Asia Pacific Diabetes Drugs Market 2019-2027 ($ Billion)
Figure 2 Asia Pacific Diabetes Drugs Market, By Type 2 Diabetes 2019-2027 ($ Million)
Figure 3 Average Life Expectancy At Birth In 2017, By Gender (In Years)
Figure 4 Porter’s Five Forces Analysis Of Diabetes Drugs Market
Figure 5 China Diabetes Drugs Market 2019-2027 ($ Million)
Figure 6 India Diabetes Drugs Market 2019-2027 ($ Million)
Figure 7 Australia Diabetes Drugs Market 2019-2027 ($ Million)
Figure 8 Japan Diabetes Drugs Market 2019-2027 ($ Million)
Figure 9 South Korea Diabetes Drugs Market 2019-2027 ($ Million)
Figure 10 Indonesia Diabetes Drugs Market 2019-2027 ($ Million)
Figure 11 Malaysia Diabetes Drugs Market 2019-2027 ($ Million)
Figure 12 Philippines Diabetes Drugs Market 2019-2027 ($ Million)
Figure 13 Thailand Diabetes Drugs Market 2019-2027 ($ Million)
Figure 14 Vietnam Diabetes Drugs Market 2019-2027 ($ Million)
Figure 15 Rest Of Asia-pacific Diabetes Drugs Market 2019-2027 ($ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report